Australia markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7169+0.0099 (+1.40%)
As of 02:30PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 127.63M
Enterprise value 107.71M
Trailing P/E N/A
Forward P/E 1.29
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.51
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.79

Trading information

Stock price history

Beta (5Y monthly) 1.51
52-week change 3-44.77%
S&P500 52-week change 322.43%
52-week high 31.4500
52-week low 30.6000
50-day moving average 30.7872
200-day moving average 30.7929

Share statistics

Avg vol (3-month) 3899.43k
Avg vol (10-day) 31.18M
Shares outstanding 5180.52M
Implied shares outstanding 6180.52M
Float 8148.24M
% held by insiders 16.82%
% held by institutions 115.07%
Shares short (15 Apr 2024) 413.19M
Short ratio (15 Apr 2024) 414.28
Short % of float (15 Apr 2024) 48.99%
Short % of shares outstanding (15 Apr 2024) 48.29%
Shares short (prior month 15 Mar 2024) 412.18M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 309 June 2017
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 309 June 2017

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-23.21%
Return on equity (ttm)-40.97%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -38.82M
Net income avi to common (ttm)-39.33M
Diluted EPS (ttm)-0.2600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)20.35M
Total cash per share (mrq)0.13
Total debt (mrq)428.57k
Total debt/equity (mrq)0.50%
Current ratio (mrq)5.06
Book value per share (mrq)0.53

Cash flow statement

Operating cash flow (ttm)-30.37M
Levered free cash flow (ttm)-16.83M